Nephrology Review

**Kidney Disease: Guidelines for Primary Care - Kimberly L. Harper, MD and Michael G. Shlipak, MD, MPH**

Counsel patients about lifestyle modifications and appropriate blood pressure goals; Review effects of antihypertensive agents in proteinuric hypertensive nephrosclerosis and diabetic nephropa-thy; Describe novel antihypertensive agents; Use revised guidelines for staging chronic kidney disease; and Select appropriate therapy for patients with renal artery stenosis.

**Topics in Nephrology - Hassan N. Ibrahim, MD, MS and Florence N. Hutchinson, MD**

Summarize the findings of several landmark trials addressing management of anemia in the setting of CKD; Estimate the optimal target hemoglobin level for erythropoiesis-stimulating agent therapy in patients with CKD; Recognize the clinical features of and differentiate between nephritic and nephrotic syndromes; Perform a thorough diagnostic evaluation of a patient with suspected nephritis or nephrosis; and Appropriately manage edema and proteinuria in patients with nephrotic syndrome.

**Topics in Nephrology - Steven C. Borkan, MD and Derek M. Fine, MD**

Recognize the limitations of the estimated glomerular filtration rate (eGFR) in the recognition and diagnosis of the stages of CKD; Utilize proteinuria screening to assess the risk for cardiovascular morbidity and mortality in a patient with CKD; Monitor for and manage secondary hyperparathyroidism in patients with CKD; Identify and avoid medications that, when used with statins, may interact and cause RM; and Diagnose RM and initiate therapy early.

**Kidney Cancer - Brian I. Rini, MD, Marc Ernstoff, MD, and Wade J. Sexton, MD**

Explain the role of vascular endothelial growth factor (VEGF) inhibition in the treatment of renal cell carcinoma (RCC); Identify patients for whom delayed or intermittent therapy is reasonable and/or desirable; Evaluate data from studies of melanoma and consider their implications for the treatment of RCC; Recognize the role of immunity and immune response in the evaluation and treatment of RCC; and Determine which patients with RCC are most likely to benefit from performance of renal biopsy.

**Kidney Cancer - John D. Seigne, MD and Wade J. Sexton, MD**

Apply established risk factors to assess prognosis of kidney tumors; Discuss current clinical trials for patients with kidney cancer; Select specific chemotherapies and immunotherapies based on patient and tumor characteristics; Weigh the benefits of nephroureterectomy against nephron-sparing approaches for patients with upper urinary tract transitional cell carcinoma; and Minimize and manage surgical complications in patients with upper urinary tract transitional cell carcinoma.

NP1A